Health Catalyst price target lowered to $7 from $8 at Stephens

Stephens analyst Jeff Garro lowered the firm’s price target on Health Catalyst to $7 from $8 and keeps an Equal Weight rating on the shares. A “beat-and-maintain quarter” plus reaffirmation of early 2025 goals of double-digit revenue growth and 50% EBITDA growth “rebuffed recent negative sentiment,” the analyst tells investors in a post-earnings note.